Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:DDOG News 17 October 2025 - 4 February 2026

Intuit stock drops 11% after-hours as AI disruption fears spread — what investors watch next

Intuit stock drops 11% after-hours as AI disruption fears spread — what investors watch next

Intuit shares plunged 10.9% to $434.09 in after-hours trading Tuesday, after falling 11% during the session. The S&P 500 software and services index dropped 3.8%, with Salesforce, Datadog, Adobe, Synopsys, and Atlassian also down sharply. The Nasdaq Composite lost 1.4%. Analysts cited aggressive repricing of software stocks as AI offerings from Anthropic raised concerns over future growth and competition.
4 February 2026
·········
Salesforce stock heads into Monday after software rout as AI fears hang over CRM shares

Salesforce stock heads into Monday after software rout as AI fears hang over CRM shares

Salesforce shares closed Friday at $212.29, down 0.8%, after plunging 7.1% Thursday amid a broad software selloff. Concerns over AI’s impact on software subscription models weighed on the sector. Investors are awaiting U.S. jobs data on Feb. 6 and Salesforce’s earnings later this month. Wall Street indexes also fell Friday on economic and political developments.
31 January 2026
······
Datadog stock jumps 7% on Stifel upgrade — what traders are watching into earnings

Datadog stock jumps 7% on Stifel upgrade — what traders are watching into earnings

Datadog shares rose 7.2% to $132.35 by midday Thursday after Stifel upgraded the stock to “buy” but cut its price target to $160 from $205. The company will report fourth-quarter and full-year results on Feb. 10, with an investor day set for Feb. 12. Other firms, including TD Cowen and Mizuho, also lowered price targets but maintained positive ratings. Observability peers Dynatrace and Elastic also advanced.
22 January 2026
··
Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

Snowflake stock slides again after Barclays downgrade; traders eye next earnings date

Snowflake shares dropped 1.4% to $206.52 by midday Wednesday, extending losses after Barclays downgraded the stock and cut its price target to $250. The stock remains below its 200-day moving average after falling 5.1% Tuesday. Broader tech shares also declined, with the Invesco QQQ Trust down 1.6%. Trading volume in Snowflake was heavier than usual following the downgrade.
14 January 2026
····
MongoDB stock drops about 4% in late trade as software sector slides — what’s next for MDB

MongoDB stock drops about 4% in late trade as software sector slides — what’s next for MDB

New York, January 2, 2026, 15:34 ET — Regular session MongoDB, Inc. shares slid about 4% in afternoon trading on Friday, falling to around $402 and underperforming the broader market as software stocks weakened on the first trading day of 2026. The move matters because MongoDB trades like a classic “risk-on” software stock — the kind that can swing hard when investors reassess valuations and interest-rate expectations. “Stocks trade expensive on 18 of 20 measures,” Bank of America equity and quant strategist Savita Subramanian wrote in a note. Reuters Software was a notable drag: the iShares Expanded Tech-Software Sector ETF
2 January 2026
····
Datadog (DDOG) Stock Today: AI Agent Launch, Q3 Earnings Momentum and Wall Street Forecasts — 2 December 2025

Datadog (DDOG) Stock Today: AI Agent Launch, Q3 Earnings Momentum and Wall Street Forecasts — 2 December 2025

Datadog, Inc. (NASDAQ: DDOG) is back in the spotlight on December 2, 2025, as the observability and security platform rolls out a major AI product, meets investors at a key technology conference and continues to digest a powerful Q3 earnings beat. As of midday trading, Datadog shares change hands around $156.5, down slightly on the session, with recent data putting the market capitalization near $56 billion and the stock still trading at a premium valuation relative to current earnings. StockAnalysis+2MarketBeat+2 Below is a detailed look at today’s news, fresh forecasts and the latest analysis driving Datadog’s stock narrative. 1. Datadog
2 December 2025
····
GitLab Stock Rockets 11% on Datadog Buyout Buzz – AI Moves and Analyst Reactions

GitLab Stock Rockets 11% on Datadog Buyout Buzz – AI Moves and Analyst Reactions

GitLab Shares Surge on Takeover Speculation GitLab Inc.’s stock skyrocketed on October 16 following fresh buyout rumors. Shares jumped 10.6% intraday – from the mid-$40s to a $48.27 close – after a report that cloud-monitoring firm Datadog (DDOG) may be preparing a takeover bid ts2.tech. The rumored offer, above $60 per share, represents a hefty premium. Traders leapt at the news: GTLB’s ~11% one-day gain far outpaced the broader market, and volume exploded to ~19 million shares (about seven times the usual daily average) ts2.tech. The Datadog-GitLab chatter originated with a StreetInsider report and quickly spread on trading desks. According
17 October 2025
····

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop